The Patent Eligibility Restoration Act (PERA) and the Promoting and the Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act have continued to face attacks from anti-patent groups. One recent example is an article published by the Electronic Frontier Foundation (EFF), which argues that PERA and PREVAIL would “make the patent system even worse” and
C4IP is recognizing William Kroll, who revolutionized America’s high-tech industries by making mass production of titanium possible. Kroll was born in Luxembourg in 1889 and studied engineering in Germany before returning to his home country and inventing a process to produce pure titanium, a strong yet lightweight metal that had previously been difficult to obtain.
As December draws to a close, we wish you and yours a very happy holiday season and a wonderful New Year! We look forward to a productive 2025, and we thank you for your continued support. December Highlights: Advancing the RESTORE Patent Rights Act The bipartisan RESTORE Patent Rights Act, introduced in July by a
Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From hospitals to housework, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of December: 1948: On December 14, David Slovin received a patent for
C4IP is recognizing Philo T. Farnsworth, who revolutionized news and entertainment with his invention of the electronic television. Farnsworth was born in Utah in 1906 and was an avid scientist from a young age, learning about electronics from science magazines. He developed the idea for the electronic television — a device that could produce images
Seokbeom Kwon, a systems management engineering professor at Sungkyunkwan University in South Korea, published a journal article in Science claiming that over a quarter of U.S. patents on inventions derived from federally funded research do not disclose that funding as required by law. Kwon also claimed that research is less likely to acknowledge government research
November was a productive month for C4IP! Here’s a roundup of all that we accomplished over the past month. November Highlights: Reforming Patent Adjudication With PREVAIL The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act remains one of the most important innovation policy priorities under consideration in Congress. The landmark bill would reform
Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From high-tech devices to holiday festivities, every aspect of our lives has benefited greatly from IP, as shown by these historical examples from the month of November: 1967: On November 14, Theodore Maiman received a
C4IP Co-Chair and former USPTO Director Andrei Iancu recently published an opinion piece in The Hill that discusses the current confusion around patent eligibility and explains how the Patent Eligibility Restoration Act (PERA) will “set matters right.” Should modern inventions like genetic blood tests to detect disease biomarkers or artificial intelligence be patent-eligible? According to
Former U.S. Ambassador to China, U.S. Secretary of Commerce, and Governor of Washington Gary Locke recently authored an opinion piece in the Minnesota Star Tribune highlighting the importance of two bipartisan bills to Minnesota’s innovation ecosystem. According to Locke, the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act and the Patent Eligibility Restoration
C4IP is recognizing William Shockley, John Bardeen, and Walter Brattain, whose invention of the transistor made modern electronics possible. Shockley, Bardeen, and Brattain met in the 1940s at Bell Laboratories when they were hand-picked to work on developing a transistor, a device for generating and amplifying electrical signals. The trio succeeded after just two years,
Activists affiliated with the Initiative for Medicines, Access & Knowledge (I-MAK) and R Street Institute have propagated false narratives about how patents stifle competition in the drug industry and keep generic drugs from coming to market. These erroneous arguments include the ideas that drug developers ‘game’ the FDA’s Orange Book, that they file unnecessary patents
